This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective To determine whether treatment with escitalopram compared with placebo would lower CSF β-amyloid 42 (Aβ42) levels.
Rationale Serotonin signaling suppresses Aβ42 in animal models of Alzheimer disease (AD) and young healthy humans. In a prospective study in older adults, we examined dose and treatment duration effects of escitalopram.
Methods Using lumbar punctures to sample CSF levels before and after a course of escitalopram treatment, cognitively normal older adults (n = 114) were assigned to placebo, 20 mg escitalopram × 2 weeks, 20 mg escitalopram × 8 weeks, or 30 mg escitalopram × 8 weeks; CSF sampled pretreatment and posttreatment and within-subject percent change in Aβ42 was used as the primary outcome in subsequent analyses.
Results An overall 9.4% greater reduction in CSF Aβ42 was found in escitalopram-treated compared with placebo-treated groups (p < 0.001, 95% confidence interval [CI] 4.9%–14.2%, d = 0.81). Positive baseline Aβ status (CSF Aβ42 levels <250 pg/mL) was associated with smaller Aβ42 reduction (p = 0.006, 95% CI −16.7% to 0.5%, d = −0.52) compared with negative baseline amyloid status (CSF Aβ42 levels >250 pg/mL).
Conclusions Short-term longitudinal doses of escitalopram decreased CSF Aβ42 in cognitively normal older adults, the target group for AD prevention.
Clinicaltrials.gov identifier NCT02161458.
Classification of evidence This study provides Class II evidence that for cognitively normal older adults, escitalopram decreases CSF Aβ42.
Glossary
- 5-HT=
- 5-hydroxytryptamine;
- Aβ=
- β-amyloid;
- AD=
- Alzheimer disease;
- ANCOVA=
- analysis of covariance;
- CDR=
- Clinical Dementia Rating;
- CI=
- confidence interval;
- CV=
- coefficient of variation;
- ISF=
- interstitial fluid;
- LMX=
- Luminex immunoassay;
- LP=
- lumbar puncture;
- MS=
- mass spectrometry;
- Penn=
- University of Pennsylvania;
- QC=
- quality control;
- SSRI=
- selective serotonin reuptake inhibitor;
- UPLC=
- ultraperformance liquid chromatography;
- WU=
- Washington University
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
See page 859
Class of Evidence: NPub.org/coe
Podcast: NPub.org/b1e5l5
- Received October 23, 2019.
- Accepted in final form June 8, 2020.
- © 2020 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.